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ABSTRACT 
Burkholdena pseudomallei is the causative agent of melioidosis, a disease endemic in Southeast Asia 
and NorthemAustralia. The bacteria cause infection via subcutaneous or inhaled routes, resulting 
in either acute lethal sepsis or chronic and eventually fatal disease. Currently no licensed vaccine 
is available to provide protection against this pathogen. In this study, eleven DNA vaccines 
encoding the B. pseudomallei proteins were constructed and used to immunise mice and 
subsequent protective capability analysed following live challenge with B. pseudomallei. 
Mice immunised with DNA vaccines encoding Hagl; Hag2 and heat shock protein demonstrated 
the greatest level of protection against bacterial infection, however, the levels of protection seen 
were still quite limited. There was no increase in survival seen following immunisation with the 
remaining· eight vaccines. This study highlights the challenges in designing vaccines against 
B. pseudomallei and suggests that a successful DNA, vaccine may need to be used in conjunction 
with adjuvant such as CpG oligodeoxynuc1eotide,· or combined in a prime-boost regime with 
recombinant protein in order to increase protective capabilities. 
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Development of DNA Vaccines Against 
Burkholderia pseudomallei 
Executive Summary 
ADF personnel are at risk of being exposed to biological warfare (BW) agents deliberately 
released by an enemy, and to agents naturally occurring in environments where they are 
. deployed. One such agent is Burkholderia pseudomallei, an intracellular bacterium that is the 
causative agent of melioidosis, a disease endemic in Southeast Asia and Northern 
Australia. The bacteria cause infection via subcutaneous or inhaled routes, resulting in 
either acute lethal sepsis or chronic and eventually fatal disease. Currently there is no 
licenced vaccine to protect against infection with this bacteria. 
Recently, scientific advances have seen the use of recombinant DNA techniques to 
produce DNA vaccines. DNA vaccines act by providing the host with a set of instructions 
for the synthesis of an encoded bacterial or viral protein. The host cell utilises this 
information to synthesise the protein, which interacts with the host immune system to 
generate the immune response and provide protection against disease. 
This report describes the construction and assessment of eleven DNA vaccines against 
B. pseudomallei. The vaccines are encoded with known virulence factors against 
B. pseudomallei and proteins shown to be immunogenic in other bacteria. Following 
construction, the eleven vaccines were assessed in a mammalian cell culture system to see 
if the encoded protein could be synthesised in vitro. Once it had been demonstrated that 
the constructs contained all the necessary components to produce the protein in 
mammalian cells, they were then used to vaccinate mice to determine levels of protection 
when mice were given a lethal dose of B. pseudomallei. 
Mice immunised with DNA vaccines encoding Hagl, Hag2 and heat shock protein 
demonstrated the greatest level of protection against bacterial infection, however, the 
levels of protection seen were still quite limited. There was no increase in survival seen 
following immunisation with the remaining eight vaccines. This study highlights the 
challenges in designing vaccines against B. pseudomallei. They may need to be used in 
conjunction with adjuvant, or in combination with recombinant protein boosting in order 
to provide protective immunity. 
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1. Introduction 
DNA vaccines, a new generation vaccine technology, have the potential to prevent various 
infectious diseases and have several advantages over conventional vaccine strategies. They 
pose significantly less risk of side effects than live attenuated vaccines, are cheap to 
manufacture, have no reliance upon cold chain [1], and can evoke strong cytotoxic 
lymphocyte (CTL) responses, which are often lacking in strategies such as recombinant 
protein. vaccination [2]. 
Burkholderia pseudomallei is the causative agent of melioidosis, a potentially fatal disease 
endemic in sub-tropical areas of South East Asia and Northern Australia, including areas such 
as Darwin and Townsville,.where military exercises are conducted. It is also considered a 
potential biowarfare agent, due to high pathogeniCity, ease of aerosolisation, and the 
prolonged therapy required to treat subsequent disease. It is therefore of interest to the 
military to develop an effective vaccine against this pathogen. Due to the intracellular nature 
of the bacteria, an effective vaccine would have to evoke not only an antibody response but 
also a strong cellular based response. A DNA vaccination strategy would provide a means of 
activating both the humoral and cellular arms of the immune system [3-5]. 
The following report describes the construction and assessment of the immunogenicity and 
protective capabilities of eleven DNA vaccines targeting B. pseudomallei. Six putative 
B. pseudomallei proteins were selected for evaluation as candidate antigens for DNA vaccine 
development against melioidosis based upon the original B. pseudomallei K96423 genome 
annotation. These were selected on the basis of homology to virulence factors in other 
pathogens and reports of known lrnrnunogenicity properties in other bacteria. These included 
B. pseudomallei flagellin (FliC), the chaperonin/ heat shock protein (HSP) encoded by GroEL, 
homologues to E. corrodens Hag2haemagglutinin, E. coli 0157:H7 outer membrane protein A 
(Ol'v1P A), C. acidovorans outer membrane porin protein (OPC), and a novel protein designated 
AirnA. 
In addition, Dstl, Porton Down had previously investigated recombinant protein vaccination 
with another five potential B. pseudomallei antigens, and the encoding sequences of these 
proteins were provided to us to enable construction of the corresponding DNA vaccines used 
in this study. These gene sequences encoded homologues to adhesins such as pneumoccoccal 
surface protein A (psA) and haemagglutinin (Hag1), enzymes such as urease and cardiolipin 
synthase (CS), and a putative transmembrane protein (Tl'v1P). 
Following construction of the vaccines, subsequent analysis of their efficacy to protect against 
infection in a mouse model was undertaken, with survival and bacterial clearance from the 
spleen assessed in immunised mice.following chiillenge with live B. pseudomallei. 
In addition, a secondary trial was also performed, immunising mice with multiple DNA 
vaccine constructs in an effort to synergistically enhance any protection seen following single 
antigen DNA vaccination. 
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2. Materials and Methods 
2.1 Bacterial strains and plasmids 
Genomic DNA was extracted from Burkholderiapseudomallei 08 strains obtained from Griffith 
University. The pGem T-easy vector was purchased from Promega and the pcrllTOPO and 
pcDNA3.1 V5-His vectors were purchased from Invitrogen. The generallaboratcJrY strains of 
E. coli used in this study included TOPO Topl0F' (Invitrogen) and DH5a (Stratagene). 
Bacterial cultures were grown overnight in LB broth (Sigma) at 37 °C with vigorous shaking. 
Where appropriate, cultures were supple~ented with 50 Ilg / rnl ampicillin. 
2.2 Polymerase Chain Reaction (PCR) 
The PCR mixture contained 10 ng genomic ONA template, 40 pmol of both the sense and 
antisense oligonucleotide primers for each amplicon (synthesised by GeneWorks) as indicated 
in Table 1, 2x Failsafe™ Buffer F, 1.25U Failsafe™ enzyme in a total volume of 25 Ill· The 
thermal cycling parameters, performed using a Peltier Thermal Cycler-200 (MJ Research), 
were as follows: 94 °C for 5 minutes, 50 °c for 30 seconds, 72 °C for 2 minutes followed by 30 
cycles of 94 °C for 30 seconds, 55 °C for 15 seconds, 72 °Cfor 90 seconds. A final cycle of 94 'C 
for 30 seconds, 55 °C for 15 seconds and an extension of 72 °C for· 5 minutes concluded the 
thermal cycling. PCR generated DNA was visualised by UV light after electrophoresis 
through a 1% w/v agarose gel in TAE (40 mM Tris-Acetate, lrnM EDTA) containing 
0.5 Ilg/ rnl ethidium bromide. 
Table 1: Oligonucleotides used for amplification of B. pseudomal/ei gene targets 
Antigen Sense 51_ 3' Antisense 5'- 3' 
AimA atctagaggctcgatcgtcgacaag ggtctagagatcgaggtaccCgtgccg 
Heat Shock Protein atctagagctaaagacgtcgtattcgg ggtctagacggagcgtcttccttcg 
FliC acggctctagaggaatcaacagcaacattaactcg agaggtctagattgcaggagcttcagcacttg 
OMPA acggctctagagcgtttccgcaagootattccg aga&:,otctagacttttgcttgatgcggatttcc 
Hag2 acggctctagaagcccagcctggcgcttag agaggtctagagtcgagcagatgtgatcggg 
OPC acggctctagagttatgctcgcaacatggctg agaggtctagagaaagcatgttgaatccccgc 
PsA atctagagcctcttgttcgtcgcgctcg agaggtctagaggcgccgagcgcgtcgagctg 
Hagl acggctctagaaggaatgaggtcgtgaacagg agaggtctagattccacctgctggaagagtc 
Urease acggctctagaagggcgtacgcggaaatgtacgg agaggtctagagaacaggaagtagcgttgcgcc 
Cardiolipin Synthase acggctctagaaccctcgactggctccatctcgg gaggtctagagaacagccgtgcgacgtgcatcgcc 
Transmembrane Protein acggctctagacagcaccgatatctgacccagg agaggtctagagccgctcgcgctcgcgttgac 
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2.3 Recombinant DNA techniques 
DNA ligations, restriction endonuclease digestion and agarose gel electrophoresis were 
performed according to standard techniques [6]. Enzymes were purchased from Promega. 
DNA was purified from agarose gels using the Perfectprep Gel Cleanup Kit (Eppendorf) as 
per manufacturer's recommendations. Following ligation of DNA fragments, plasmid DNA 
was introduced into E. coli cells, made competent by calcium chloride, using the heat shock 
method [6]. 
2.4 Plasmid DNA preparation 
Small-scale plasmid DNA preparations were extracted from 1.5 m! of a bacterial culture that 
had been grown overnight in LB broth (Sigma) supplemented with 50 I-lg 1m! ampicillin. 
Plasmid DNA was extracted from the bacterial cells using the Promega Wizard plasmid 
purification kit as per manufacturer's recommendations: 
Large scale plasmid DNA preparations were performed on 500 m! bacterial cultures using the 
Qiagen Plasmid Maxi Kit as per manufacturer's recommendations. 
2.5 Transfection of 293 cells 
Six well plates were seeded with 1xl06 293 cells per well in 2 m! of growth medium (5% 
Bovine Calf Serum (ThermoTrace) I SF-DMEM (Gibco - Life Technologies) I 50 I-lg 1m! 
penicillin-streptomycin) and incubated overnight at 37°C, 5% C02. Two micrograms of 
plasmid DNA in 250 !ll SF-DMEM (Gibco) per well to be transfected, was added to 10!ll of 
Lipofectarnine 2000 (Invitrogen) in 250l-l1 of SF-DMEM that had been pre-incubated for 5 mins 
at room temperature. The mixture was then incubated for 20 minutes at room temperature. 
The cells were washed with 1 m! SF-DMEM, and 2 m! of SF-DMEM added to cover the cell 
monolayer. The plasmid DNA-Lipofectarnine 2000 mixture was added to the appropriate 
well containing the cell monolayer in 2 m! of SF-DMEM and the plate incubated for 6 hrs at 
37°C, in an atmosphere containing 5% C02. The 2ml of SF-DMEM was removed and replaced 
with 2m! of the growth medium. The cells were then incubated for a further 24 hrs at 37°C, 
5% C02. 
After the addition of 1m! of PBS, the cells were scraped from the plate using a spatula and 
transferred into a microfuge tube. The cells were washed two times by the addition of 500 ul 
of PBS followed by centrifugation at 200 g for 5 minutes to pellet the cells. The final cell pellet 
was resuspended in 100 ul of lysis buffer and incubated on ice for 15 minutes. The solution 
was then passed through a 22-gauge needle 10 times to shear the DNA. 
2.6 Polyacrylamide gel electrophoresis 
The harvested cells were prepared for PAGE by resuspending them in an equal volume of 2x 
Laemmli sample buffer (Sigma) (12.2 mM Tris-Hel pH 6.8, 20% Glycerol v lv, 4 % SDS w lv, 
10% ~-Mercaptoenthanol v/v, 0.004% Bromophenol Blue w/v) and the sample heated to 
100 °C for 5 mins, before loading the cell extracts onto a polyacrylamide gel. The prepared 
3 
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samples were separated by electrophoresis through a 12.5% homogeneous SDS 
polyacrylamide PhastGel (Eharmacia Biotech) as per manufacturer's instructions. Low range, 
pre-stained, molecular weight standards (BioRad) were also loaded onto the polyacrylamide 
gel to enable molecular weight comparisons. Following electrophoresis, gels were either 
stained with Coomassie Blue (Sigma) or electrophoretically transferred to a nitrocellulose 
membrane (BioRad) for western blotting using the PhastSystem (Pharmacia Biotech) as per 
manufacturer's instructions. 
2.7 Western blot analysis 
Western blot analysis was performed using standard techniques. In brief, following blocking 
of the membrane in 10 ml of blocking buffer (5 % milk powder in PBS -Tween 20 [Sigma]) for 
Ihr at room temperature the membrane was washed twice in 20 ml of PBS-Tween 20. The 
membrane was then incubated in 5 ml of blocking buffer containing Anti-V5 antibody 
(Invitrogen) at a dilution of 1:5000, for 2 hrs at room temperatUre, with shaking. For the 
western blots developed by ECL, the membrane was washed twice in 20 ml of PBS-Tween 20 
and incubated in 15 ml of blocking buffer containing goat anti-mouse IgG horse radish 
peroxidase conjugate (Sigma) at a dilution of 1:30000 for Ihr at room temperature. Following 
washing of the membrane twice in 20 ml of PBS-Tween 20, proteins recognised by the Anti-V5 
antibody were visualised by developing the blot onto x-ray film using ECL and Western 
Blotting Detection kit as per manufacturer's instructions (GE Healthcare). For the western blot 
developed using BCIP /NBT, a goat anti-mouse IgG alkaline-phosphatase conjugate (Sigma) 
was used as the secondary antibody for Ihr at RT, at a dilution of 1:2000 in blocking buffer. 
The blot was then washed twice as above, and developed using BCIP /NBT (Sigma) as per 
manufacturer's instructions. 
2.8 Preparation of DNA micro carriers for gene gun immunisation 
The preparation of the microcarriers was performed as described in the Biorad Helios Gene 
Gun System instruction manual using a microcarrier loading quantity (MLQ) of 0.5 mg/ shot 
of gold and DNA loading ratio (DLR) of 1 /J-g/ shot of plasmid for· single plasmids, or a DLR of 
3 /J-g/ shot (1 JIg each antigen) for multiple plasmids. In brief, 100 iJ.l of 0.05 M spermidine was 
added to the required amount of gold and vortexed. The designated concentration of plasmid 
DNA was then added, followed by the dropwise addition of100 iJ.lIM CaCh while vortexing. 
The mixture was allowed to precipitate at room temperature for 10 min, then spun to pellet 
the gold, and the supernatant discarded. The pellet was then washed three times with 100% 
ethanol, before resuspension in ethanol containing the appropriate concentration of 
polyvinylpyrolidone (pVP).The gold/plasmid suspension was then coated onto tubing, and 
0.5 inch cartridges prepared. In order to ensure quality control of cartridges, random-samples 
of 2 cartridges per batch were selected for assessment of DNA load. The cartridges were 
resuspended in 200 iJ.l Tris-EDTA and sonicated to strip the gold/DNA off the tubing. The 
gold was pelleted by centrifugation and the supernatant run on a 1% SDS-PAGE gel to 
visualise the DNA. Additionally, 2 cartridges per batch were resuspended in 500 J1l Tris-
EDTA and sonicated, and the gold pelleted as above, then the supernatant was read at OD260 
to determine the concentration of DNA on the cartridges. 
4 
DSTO-1N-0872 
2.9 Immunisation of mice 
2.9.1 Preliminary single antigen animal trial 
Groups of 13 Balbi c mice were intradermally (ID) immunised on day 0, day 14 and day 28 
with one of the following or the' pcDNA3.1start vector [7] that did not contain any 
B. pseudomallei genes. Ten mice from each group were identified for monitoring survival, 3 for 
calculation of bacterial loads and ID immunisation was achieved using the Helios gene gun 
(Biorad), which delivered 2 !-Ig DNA at 300 psi into the shaved abdomen of each mouse. On 
day 42 animals in the survival/bacterial load studies were challenged with live B. pseudomallei 
NCTC 13179 as detailed below. 
2.9.2 Multiple antigen animal trial 
Groups of 15 Balbi c mice were intradermally immunised on day 0, day 14 and day 28 with 
either 2 ].Ig of DNA vaccine encocling HSP, Hag2, Haemagglutinin, or urease alone, or a 
combination DNA vaccine containing 2 ].Ig of each plasmid coated onto the one gene gun 
bullet. One control group received the pcDNA3.1start vector and the other control group 
remained unvaccinated. Ten mice from each group were monitored for survival following 
challenge with live B. pseudomallei. The remaining five mice in each group were used to 
calculate bacterial loads as described below. 
2.10 Challenge with Burkholderia pseudomallei 
B. pseudomaZZei NCTC 13179, was plated onto blood agar .48 hours prior to challenge and 
incubated af37 0c. A dose of 9.4x10scfu (approximately 2xLDso) as described by [8], was used 
to challenge the vaccinated mice. A suspension of 1x10B cells was made up in sterile PBS with 
an optical density reading at 650 TIm of 0.198. The dose was then diluted to achieve the 
required concentrations in 200 !-II and the suspension was then placed into syringes. The mice 
were infected with the bacteria via intraperitoneal inoculation and monitored for 10-14 days 
for survival and any moribund mice were euthanised using CO2 asphyxiation. 
To determine the precise inoculum dose for the mice, ten-fold serial dilutions were made in 
PBS and 20 !-II of each dilution were plated in triplicate onto AshdoWn's agar and incubated at 
37°C for 24-48 hours. The colonies were counted and the dose was calculated. 
2.11 Bacterialloads 
Bacterial loads were carried out on 3-5 mice from each immunisation group at three days after 
challenge with B. pseudomallei NCTC 13179. Mice were euthanised via C02 asphyxiation. 
Spleens were removed aseptically and placed into a stomacher bag with PBS. The bags were 
then placed into a stomacher until the spleens were homogenised. Ten-fold dilutions were 
made from the homogenate and 20 !-II aliquots plated onto Ashdown's agar in triplicate and 
incubated for 24-48 hours. The colonies were counted and the concentration of bacteria in the 
whole spleen calculated. 
5 
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2.12 Western Blot using Melioidosis patient sera 
Western blot analysis was performed using standard techniques. In brief, folloWing blocking 
of the membrane in 10 rnl of blocking buffer (3 % milk powder in PBS -Tween 20 [Sigma)) 
overnight at 4°C, the membrane was washed twice inPBS-Tween20. The membrane was then 
incubated in 5 rnl of blocking buffer containing sera from melioidosis patients or negative 
control sera at a dilution ofl:500, for 1 hr at room temperature, with shaking. The membrane 
was washed twice in 20 mI of 1% NaCI in PBS-Tween 20 to help reduce non-specific 
background, followed by two washes in 20 mI of PBS-Tween 20. The blots were then 
incubated in 15 rnl of blocking buffer containing goat anti-human IgG horseradish peroxidise 
conjugate (Sigma) at a dilution of 1:50000 ~or 1hr at room temperature. Following washing of 
the membrane twice in 20 rnl ofl % NaCl ill PBS-Tween 20 followed by two washes in 20 rnl of 
PBS-Tween 20, proteins recognised by patient sera were visualised by developing the blot 
onto x-ray film using ECL and Western Blotting Detection kit as per manufacturer's 
instructions (GE Healthtare). 
3. Results 
3.1 Construction of DNA vaccines 
The genetic sequences of eleven putative B. pseudomallei antigens were obtained either as the 
result of BLAST searches against homologous sequences from other organisms, or as encoding 
sequences of recombinant protein vaccines produced by Dstl, Porton Down. The identified 
full sequences were amplified by PCR using genomic DNA from the 08 B. pseudomallei strain 
as template, with the exception of the PsA sequence, which failed to amplify under several 
different PCR conditiOns, and was subsequently truncated at the 3' (N-terminus) end to 
enable successful amplification of the product. The acquired PCR products were then ligated 
into the intermediate vector pcrIITOPOTM (Invitrogen). The sequence was then excised and 
sub-cloned into the mammalian expression vector pcDNA3.1start [7] to create the DNA 
vaccine constructs listed in Table 2. 
Table 2: Gene products encoded by the DNA vaccine constructs 
DNA Vaccine Construct Gene Product 
pBpsI30 Novel protein (MmA) 
pBps160 Heat shock protein (HSP) 
pBps170 Flagellin (Fliq 
pBps1100 OMPA 
pBpsl120 Hag2 
pBps1130 OPC 
pBps1140 PsA 
pBpsllS0 Hagl 
pBps1160 Urease 
pBps1170 Cardiolipin synthase (CS) 
pBps1180 Transmembrane protein (TMP) 
6 
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In order to assess whether the encoded B. pseudomallei sequences could be successfully 
translated into protein antigen within mammalian cells, the DNA vaccines were transfected 
via a lipoprotein carrier into human HEK 293 kidney cells in vitro, and the subsequent protein 
expression analysed by separating the lysed cell extracts by PAGE and probing with an anti-
V5 antibody that recognised the V5 epitope engineered to the carboxy terminal of the protein. 
The molecular weight estimated for the detected proteins correlated with the expected 
molecular weight of the B. pseudomallei antigens encoded by their corresponding DNA 
vaccines, with the exception of the PsA homolog, where the molecular weight reflected the 
truncation of the antigen sequence (Figure 2). The detection of all eleven of the B. pseudomallei 
antigens by western blot demonstrated that the engineered vaccines contained all the 
necessary information tb direct protein synthesis of the encoded proteins in a mammalian cell 
system, and provided some confidence that when introduced into mice, the vaccines should 
permit the synthesis of the encoded protein, and potentially allow for peptide display on the 
surface of transfected cells for recognition by immune cells. 
3.2 Immunisation and challenge of mice with a single DNA vaccine 
construct 
Following assessment of protein expression in vitro, preliminary animal trials were 
undertaken in order to test the protective capability of the constructed DNA vaccines. Eleven 
groups of 15 Balb / c mice received three immunisations ID with one of the DNA constructs 
over a 6 week period, and were subsequently challenged with 2xLDso B. pseudomallei NCTC 
13179 two weeks after the final immunisation. One group of mice in each trial performed were 
. sham immunised with the pcDNA3.1startvector alone as a negative control. Ten mice in each 
group were monitored for survival over a 10 day period post-challenge (Figure 3). The groups 
immunised with the Hag1, Hag2 and heat shock protein DNA vaccines showed the highest 
level of protection against bacterial infection, with percentage survival at 20%, 25 % and 20% 
respectively. One mouse was also protected in the group immunised with DNA vaccine 
encoding urease. There was no protection seen in mice immunised with the DNA vaccines 
encoding the cardiolipin synthase, the transmembrane protein, AirnA, OPe, FliC, OMP A or 
PsA. 
In addition, 3 mice per immunisation group were sacrificed on the third day post-challenge in 
order to assess the ability of immunised animals to effectively clear bacteria from the spleen. 
The spleens were homogenised and bacterial loads calculated through serial dilutions plated 
in triplicate on Ashdown's agar and incubated over 24-48hrs (Figure 4). Bacterial loads were 
unable to be determined in mice immunised withDNA vaccines encoding urease, cardiolipin 
synthase or the transmembrane protein, as all an.iIDals succumbed to challenge prior to day 3. 
Unfortunately in the remaining immunisation groups, there was no reduction in bacterial 
loads in the spleens of any of the animals, when compared to sham immunised animals, 
indicating that although some DNA vaccine constructs provided moderate protection and 
delayed time to death, they could not promote complete clearance of infection. 
7 
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3.3 Immunisation and challenge of mice with multiple DNA vaccine 
constructs 
Based on the results observed following immunisation with a single DNA vaccine construct, 
the four vaccines that provided some protection against challenge (Hag1, Hag2, HSP and 
urease) were used in a secondary animal trial to determine whether immunisation with a 
combination of all four plasmid constructs could synergistically enhance survival. Four 
groups of 15 mice received three ID immunisations at two week intervals of a single vaccine 
construct. A fifth group received all four plasmids 3 times over the same 6 week period. The 
concentrations of each vaccination dose were adjusted to ensure that mice receiving multiple 
plasmids were administered the same concentration of each antigen as those mice receiving a 
single dose. 
As with the previous trial, 10 mice from each group were assessed for survival follOWing 
challenge with 2xLD5o B. pseudomallei NCTC 13179 IF over a 10 day period. It was planned 
that the remaining five mice were to be sacrificed on day 3 post-challenge to determine 
bacterial loads in the spleen, however the majority of mice in each group succumbed to 
infection prior to this date, and therefore bacterial clearance could only be observed in 2 mice 
from each immunisation group. 
Although immunisation with multiple plasmids failed to significantly enhance any protection 
seen following vaccination with a single plasmid (Figure 5), there was some decrease in the 
bacterial loads observed in animals immunised with all four plasmids when compared with 
both sham or unvaccinated controls and also with animals immunised with the HSP or urease 
DNA vaccine alone (Figure 6), which may indicate th,,:t DNA vaccination with multiple 
antigens is more effective than single plasmid vaccination. However, due to the low number 
of animals surviving in each group when bacterial loads were assessed, it is hard to draw 
conclusions about the significance of this result. 
3.4 Western Blot using Melioidosis patient sera 
Western blot analysis was performed to determine if antibodies in human sera could 
recognise the antigens encoded by the constructed DNA vaccines. Sera was taken from two 
convalescent melioidosis patients and one uninfected individual (negative control) and 
blotted against 293 .cell extracts containing expressed protein encoded by each of the DNA 
vaccines. Untransfected 293 cell extracts were also probed with the sera to act as a negative 
control. Unfortunately there was no antigen-specific antibody recognition by either of the 
melioidosis patient serum samples (data not shown). 
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4. Discussion 
DNA vaccines provide a promising strategy for combating disease caused by intracellular 
pathogens. Often it proves hard to develop effective vaccines against these organisms, as they 
are adept at evading the host immune response, and frequently cause latent infection, 
remaining dormant for months or even years, only to re-emerge when the host is 
immunocompromised. DNA vaccines allow antigen to be synthesised intracellularly and 
presented on cell surfaces complexed with MHC 1, resulting in the activation of cellular 
immunity including CDS+ cytotoxic lymphocytes, which can then lyse infected cells and 
release cytokines to make surrounding cells resistant to subsequent infection. 
In this study eleven DNA vaccines were constructed against the intracellular pathogen 
Burkholderia pseudomallei, the causative agent of melioidosis. The vaccines were subsequently 
assessed in vitro for ability to intracellularly express the encoded antigen, and also ability to 
provide protection in Balb / c mice following administration of a lethal dose of B. pseudomallei 
NCTC13179. 
The groups of mice immunised with the Hag1, Hag2 and heat shock protein DNA vaccines 
showed the highest level of protection against bacterial infection. The increased protective 
capabilities of the heat shock protein DNA vaccine support the findings of previous studies, 
which have shown the immunogenicity of HSP, particularly when used as an adjuvant for 
DNA vaccines [9,10]. It is well e~tablished that HSPs playa significant role in innate and 
adaptive immune responses to pathogens, through interactions with antigen presenting cells, 
mediation of dendritic cell maturation, and cytokine induction [11, 12]. As a stand-alone 
vaccine it may not be a good choice, due to the highly conserved nature of the antigen across a 
wide selection of organisms, however as part of a multi-component vaccine it may enhance 
any protective responses provided by other antigens, as has been shown previously [10]. 
The Hagl and Hag2 vaccines both encode adhesins, and are considered important virulence 
factors, as these proteins have been shown to playa role in attachment of pathogens to host 
cells to facilitate invasion [13, 14]. It is expected that they may be more immunogenic than 
other antigens, as they 'are surface proteins and are therefore more likely to be recognised by 
the immune system. A homolog to Hag2 was induced in-vivo in a rat lung model of chronic 
P. aeruginosa infection [15], indicating that it may be highly expressed during infection, and 
therefore more accessible to antigen presenting cells and lymphocytes. 
Interestirigly however, the DNA vaccine encoding the hom9log of PsA, also an adhesin 
known to facilitate invasion [16], failed to induce any increase in survival. This contradicts the 
effects observed following vaccination with recombinant PsA performed by Dstl, where 
significant delay time to death was seen in immunised animals when compared with sham or 
unvaccinated controls (unpublished data). This lack of a protective response seen in our study 
may be the result of the truncation of the protein, which although led to the translated protein 
being expressed more easily, may have resulted In a change to the secondary structure, 
thereby masking epitopes that may be important in immune recognition, or even eliminating 
epitopes altogether if they were located on the truncated domain. 
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It is also surprising that there was no increase in protection following immunisation with the 
FliC vaccine, as this would appear to contradict observations from a study performed by Chen 
et ai, who found that intramuscular injection of a DNA plasmid construct encoding flagellin 
was associated with a decrease in live bacterial counts in both the liver and the spleen 
following bacterial challenge (17). This difference in responses could however be attributed to 
different vaccine delivery systems, as gene gun induced responses have been shown to differ 
from those seen following intra-muscular immunisation (18). 
Another explanation for the lack of protective response and bacterial clearance observed in 
our study could be the degree to which antigens are actually expressed by the organism in 
natural infection, a claim that is support<rd by the non-reactivity of sera taken from two 
convalescent melioidosis patients when immuno-blotted against the protein antigens (data not 
shown). 
For this reason, perhaps immunisation with plasmid DNA is not the most effective 
vaccination strategy to employ against B. pseudomallei. It may be beneficial against viral 
pathogens, where there are a limited number of structural proteins that can be encoded by the 
vaccine, thus allowing for all antigens to be incorporated into one. vaccine, and therefore 
covering a larger pool of antigens potentially on display to immune cells during natural 
infection. Butfor bacteria, in particular B. pseudomallei which has a large genome spread over 2 
chromosomes, the range of potential antigens is extensive, and by selecting a mere few, the 
chance that these antigens will be highly effective at providing protectionfrc)];n disease is quite 
smalL The limited knowledge of the mechanisms of B. pseudomallei infection also makes 
selecting effective candidateaJltigens ~uite difficult. While. certain. virulence factors that 
contribute to adherence and invasion of the organism have been quite well defined through 
mutagenesis studies, it is evident both from our study, ana from others [19], that virulence in 
B. pseudomallei infection does· not necessarily automatically translate to immunogenicity. 
Indeed, it has even been reported that in some cases, not even naturally acquired infection is 
enough to guarantee against subsequent re-infection with B. pseudomallei [20]. Reverse 
vaccinology, which uses bioinforrnatics to determine epitopes frOp:1. an entire sequenced 
genome is fast becoming the future for antigenic determination, however it seems that ·one of 
the more optimal ways of providing protection is still to use attenuated B. pseudomallei, a 
vaccine strategy that is unlikely to ever be licensed, due to the high risk of reversion of the 
bacteria to a virulent state. 
The use of multiple DNA vaccines to synergistically enhance protective responses has been 
studied in a number of pathogens, with mixed results. A study comparing single plasmid 
DNA immunisation againstM. tuberculosis with a four-plasmid multiple DNA immunisation 
regime found that the multi-plasmid immunisation not only gave a higher protective response 
than the single plasmid vaccine, but was also equivalent to the protective response seen by the 
currently licensed live BCG vaccine [21]. Similar results were also seen in studies of 
combination vaccination with HIV IHCV irnmunogens, and even with multi-plasmid vaccines 
against different targets such as B. a71.thracis, Ebola virus, Marburg and Venezuelan equine 
encephalitis [22]. However, there have also been cases where multi-plasmid vaccination has 
resulted in reduction of immune responses due to interference between antigens [23, 24]. 
Whether this is the case in our study remains to be seen, however it may be one explanation as 
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to why there was no enhancement in the protective response seen when immunising with a 
combination of antigens over immunisation with a single antigen. 
As an alternative vaccine strategy for B. pseudomallei; it may then be better to focus on non-
antigen specific means of enhancing immunity. Irrununostimulatory adjuvants such as 
oligodeoxynucleotides (ODN) containing CpG motifs have been shown to stimulate toll-like 
receptor 9 (TLR9) which is important in innate immune responses. Studies have shown that 
when CpG ODN 1826 was incorporated into a DNA plasmid construct encoding B. 
pseudomallei flagellin and was administered intra-muscularly to Balb / c mice, it enhanced both 
the Th1-specific immune response and resistance of the mice to infectivity when compared 
with animals immunised with an unmodified plasmid [25]. Indeed even when administered 
alone, CpG ODN has repeatedly shown protective capability against infection with a number 
of intracellular bacteria [26], including B. pseudomallei [27] most likely due to initial innate 
inflammatory responses subsequently facilitating the development of more specific Thl based 
immunity, with rapid stimulation of B and T cells, and enhanced production of 
immunomodulatory cytokines such as IFN-y, IL-12, IL-6 and TNF-a [26]. 
Chemical adjuvants have also proved to be quite promising in enhancing DNA vaccine 
immunogenicity in animal models. Liposomes have been shown to protect DNA from 
degradation by serum proteins [28], and cationic polymers aid in transfection and augment 
DNA expression in vivo [29]. Microparticles have also been used, by adsorbing DNA 
immunogens onto or encapsulating inside polymeric microspheres to help protect the DNA 
from degradation and also to specifically target the plasmid DNA to antigen presenting cells 
[28]. 
5. Conclusion 
This study has detailed the construction and assessment of eleven DNA vaccines encoding 
various antigens from B. pseudomallei. Although DNA vaccines have been shown in a number 
of studies to evoke strong CD8+ cytotoxic responses necessary for protection against 
intracellular pathogens, we have found in our studies that for B. pseudomallei they may not be 
the optimal delivery system to provide protection against disease in their own right. They 
may be better suited to viral pathogens, where antigen selection is limited to a few genes, as 
opposed to the numerous potential antigens for B. pseudomallei. The recommendations for the 
use of a B. pseudomallei DNA vaccine would perl1aps be to combine it either in a prime boost 
regime with recombinant protein or with use of an adjuvant such as C::pG oligonucleotide or 
chemical adjuvants such as liposomes, nanoparticles or polymers. 
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Figure 1: Constnlction of the DNA vaccines. The gene sequence encoding each B. pseudomallei 
antigenic protein was amplified from B. pseudomallei genomic DNA using peR (A). The 
amplified product was cloned into the plasmid vector peRIl-TOPO. to create an 
intermediate constnlct (B). The B. pseudomallei gene sequence was then excised from 
peRIl- TO PO by Xba I restriction endonuclease digestion (C) and subcloned into the 
modified mammalian cell expression vectorpcDNA3.1start (D), to create the DNA vaccine 
construct (E). 
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Figure 2: In vitro expression of the B. pseudomallei proteins encoded by the DNA vaccines, 
detected by western blot. The DNA plasmid constructs were transjected into mammalian 
2935 cells using a cationic lipid complex. Extracts from transfected cells and non-
transfected negative control cells were resolved by PAGE (12.5%), transferred to a 
nitrocellulose membrane and probed with anti-V5 epitope antibody. Reactive proteins were 
visualised through- a HRP-conjugated secondary antibody developed by EeL, with the 
exception of Gel (B), where reactive proteins were visualised through an alkaline-
phosphatase conjugated secondary antibody developed by BCIP/NBT. 
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Figure 3: Survival of mice following challenge with live B. pseudomallei NCTC 13179. Ten 
mice immunised with eitherpcDNA3.1start alone (sham) or a DNA vaccine encoding one 
of the following B. pseudornallei antigens: urease, cardiolipin synthase (CS), 
transmembrane protein (TMP), Ope, PsA, OMPA, Hag1, Hag2, AimA, Flie, or heat 
shock protein (HSP). Two weeks after the final immunisation, all animals received 2xLD50 
IP of live B. pseudornallei. Survival was monitored over a 10 day period post-challenge. 
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Figure 4: Bacterial loads in spleens of mice following DNA vaccination and challenge with 
live B- pseudomallei NCTC 13179. 3 mice from each immunisation group received 
2xLD5o of live B. pseudomallei NOTC 13179 IF, 2 weeks after the third DNA 
vaccination. Three days after challenge animals were sacrificed and the spleens 
homogenised. Ten-fold dilutions were made from the homogenate and plated onto 
Ashdown's agar in triplicate in 20 /ll aliquots and incubated for 24-48 hours. The colonies 
were counted and the concentration of bacteria in the whole spleen calculated. Values are 
expressed as the mean±SD 
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Figure 5: Effects of DNA immunisation with multiple B. pseudomallei antigens on survival 
followed by live challenge. Groups of ten mice were immunised with DNA vaccines 
encoding HSP, Hag1, Urease, Hag2, or a combination of all four antigens (Multi). Two 
control groups received either pcDNA3.lstart alone (sham) or remained unvaccinated. Two 
weeks after the third immunisation, mice received 2xLDso IP of live B. pseudomallei 
NCTC 13179.and survival was monitored over a 14 day period post-challenge. 
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Figure 6: Effects of immunisation with multiple B. pseudomallei antigens on bacterial 
loads in spleens of mice following challenge with live B. pseudomallei NCTC 
13179. 5 mice from each immunisation group received 2xLD50 of live B. pseudomallei 
NCTC 13179 IF, 2 weeks after the third DNA vaccination. Two days after challenge 
animals were sacrificed and the spleens homogenised. Ten-fold dilutions were made from the 
homogenate and plated onto Ashdown's agar in triplicate in 20 pi aliquots and incubated 
for 24-48 hours. The colonies were counted and the concentration of bacteria in the whole 
spleen calculated. Values are expressed as the mean±SEM 
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